Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Conduct a value analysis of cash back cards with no fees to make smart financial choices. Understand the benefits and options available.
25,276 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Cracking the code on a potential real estate rebound? play means stacking three strategic bets: affordable debt, grow...
In volatile markets, pulling back can create buying opportunities. This article highlights three growth stocks to buy...
Industrial stocks right now offer solid exposure to infrastructure spending and manufacturing demand. Meet two top pi...
Intel's stock soaring has headlines buzzing. This article breaks down the catalysts, risks, and a clear plan for inve...
A sharp, fear-driven decline hit Microsoft, but a deeper look suggests the selloff may reflect sentiment more than so...
A major fund trims a big stake in a tech name, sparking questions about risk, sector exposure, and portfolio resilien...
Institutional buyers are quietly backing a select set of artificial intelligence (ai) stock for 2026. This deep dive ...
BitMine announces a sizable addition to its Ethereum stash, buying about 61,000 ETH and boosting holdings to about 4....
If you’ve got $1,000 to invest, you don’t need to chase the hottest hype. Here are three durable stocks that recently...
When the world's wealthiest fund managers move, markets listen. This deep dive explains how the latest 13F season sho...
Peabody Energy shares fell nearly 6% after a quarterly report that missed profitability targets. This article breaks ...